Literature DB >> 2325164

Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen.

D E Brenneman1, T Nicol, D Warren, L M Bowers.   

Abstract

Vasoactive intestinal peptide (VIP) increases neuronal survival in dissociated spinal cord cultures during a critical period of development. In the present study, two mechanisms contributing to this action of VIP have been observed: 1) VIP was shown to be a secretagogue for neuron survival-promoting activity; and 2) VIP was found to be an astroglial mitogen. A high molecular weight substance (greater than 30 kDa), which increased neuronal survival in tetrodotoxin (TTX)-treated spinal cord cultures, was detected in the medium from nonneuronal cells incubated for 1 hr with 0.1 nM VIP. In addition, 3H-thymidine autoradiography and glial fibrillary acid protein (GFAP) immunocytochemistry were used to show that a 5 day treatment with (VIP) increased astroglial mitosis. This effect was specific for astroglia, as silver grain-positive cells not exhibiting GFAP immunoreactivity did not increase in number after VIP treatment. The dual action of VIP may regulate glial-derived trophic substances that are important for neuronal survival during the course of development.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2325164     DOI: 10.1002/jnr.490250316

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  31 in total

1.  A femtomolar-acting neuroprotective peptide.

Authors:  D E Brenneman; I Gozes
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

Review 2.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

3.  Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides.

Authors:  O Ashur-Fabian; E Giladi; D E Brenneman; I Gozes
Journal:  J Mol Neurosci       Date:  1997-12       Impact factor: 3.444

Review 4.  Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?

Authors:  I Gozes; D E Brenneman
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

5.  Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.

Authors:  I Gozes; J Glowa; D E Brenneman; S K McCune; E Lee; H Westphal
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

6.  Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse.

Authors:  P Gressens; J M Hill; B Paindaveine; I Gozes; M Fridkin; D E Brenneman
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.

Authors:  Christine Dufes; Céline Alleaume; Alicia Montoni; Jean-Christophe Olivier; Jean-Marc Muller
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

8.  Chronic treatment of newborn rats with naltrexone alters astrocyte production of nerve growth factor.

Authors:  K Mitsuo; J P Schwartz
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

9.  Expression of neuropeptides and neuropeptide mRNAs in spinal cord after axotomy in the rat, with special reference to motoneurons and galanin.

Authors:  X Zhang; V M Verge; Z Wiesenfeld-Hallin; F Piehl; T Hökfelt
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

Review 10.  HIV-related neuronal injury. Potential therapeutic intervention with calcium channel antagonists and NMDA antagonists.

Authors:  S A Lipton
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.